Daily viral kinetics and innate and adaptive immune responses assessment in COVID-19: a case series

Pauline Vetter^{1,2,3*#}, Christiane Eberhardt^{4*}, Benjamin Meyer^{4*}, Paola Andrea Martinez Murillo^{4*}, Giulia Torriani^{1,4}, Fiona Pigny^{1,3}, Sylvain Lemeille⁴, Samuel Cordey³, Florian Laubscher³, Diem-Lan Vu^{2,3}, Adrien Calame^{1,3}, Manuel Schibler^{2,3}, Frederique Jacquerioz^{1,3}, Géraldine Blanchard Rohner⁶, Claire-Anne Siegrist⁴, Laurent Kaiser^{1,2,3}, Arnaud M Didierlaurent^{§1,4}, Isabella Eckerle^{§1,2,3,5}

¹Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland

²Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland.

³Laboratory of Virology, Division of Infectious Diseases and Division of Laboratory Medicine, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.

⁴Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.

⁵Department of Microbiology and Molecular Medicine, University of Geneva, Faculty of Medicine, 1205 Geneva, Switzerland

⁶Department of Paediatrics, Children's Hospital of Geneva, University Hospitals of Geneva, 1205 Switzerland / Centre for Vaccinology and Neonatal Immunology, Department of Pathology-Immunology, Medical Faculty and University Hospitals of Geneva, Switzerland.

Running title: Viral and immune profiling in COVID-19

#Corresponding author.

Pauline Vetter
Geneva Center for Emerging Viral Diseases
Geneva University Hospitals
Rue Gabrielle-Perret-Gentil 4
1205 Geneva 14
Switzerland

Tel: +41 22 372 40 96; Fax: +41 22 372 40 97

Email: Pauline.vetter@hcuge.ch

* Equally contributed; § co-senior author

Key words: SARS-CoV-2, cytokines, viral load, immunity, antibody response

Summary

We describe viral and immune profiles of the first five SARS-CoV-2 patients in our institution, showing high viral loads and infectious viral shedding in early acute disease. Mild patients mount an innate response sufficient for viral control and specific immunity.

Word count: Abstract: 189 words, Manuscript: 2979 words, 1 Table, 4 Figures.

Abstract

Background

Viral shedding patterns and its correlation with the immune responses of mildly symptomatic COVID-19 patients are still poorly characterized.

Methods:

We enrolled the first five COVID-19 patients quarantined in our institution; none received immunomodulatory treatment. We monitored shedding of viral RNA and infectious virus by RT-PCR and cell culture from the upper respiratory tract, and characterized the kinetics of systemic innate and adaptive immune responses.

Results

Despite mild clinical disease, high viral loads and shedding of infectious virus were observed from the respiratory tract, with isolation of infectious virus and prolonged positivity by PCR up to day 7 and 19 post onset of symptoms, respectively. Robust innate responses characterized by an increase in activated CD14+CD16+ monocytes and cytokine responses were observed as early as 2 days after symptoms onset. Cellular and humoral SARS-CoV-2 specific adaptive responses were detectable in all patients.

Conclusion

Infectious virus shedding was limited to the first week of symptom onset in mild cases. A strong innate response, characterized by the mobilization of activated monocytes during the first days of infection, as well as SARS-CoV-2 specific antibodies were detectable, even in patients with mild disease.

Introduction

As of 18th June 2020, more than 8 million cases of COVID-19 have been reported worldwide, with 450,000 deaths [2]. While the first reports mainly described patients presenting with severe pneumonia [3], the spectrum of disease is wide, with more than 80% of infected individuals displaying moderate, mild or even no symptoms [4, 5].

Studies to date have focused on hospitalized patients with severe or critical disease. In those patients, peak viral load in the upper respiratory tract occurs during the second week post onset of symptoms (POS), while viral clearance is achieved after 10 days in more than 90% of patients with mild disease [6]. Elevated cytokine levels, including IL-6 and IP-10, increased CRP and profound T-cell lymphopenia signal disease worsening [7-10]. This dysregulated inflammatory response is thought to result from an initial impairment of interferon production and thus reduced early viral control. Several reports have suggested that SARS-CoV-2 antibody titers are higher in patients with more severe disease [3, 11]. Activated SARS-CoV-2-specific CD4 and CD8 T cells have been reported in a few studies [12-14].

Yet viral shedding and immune responses in patients with mild COVID-19, the most frequent form of disease, remain poorly characterized. Comprehensive studies investigating viral shedding and immune responses at multiple time points in these patients are lacking. Available descriptions and interpretations of viral behavior and immunological responses in more severely ill patients may be biased by the rapid implementation of immunomodulatory treatments.

In our region, the first known case of COVID-19 was identified late February 2020. In line with public health policy early in the outbreak, every confirmed patient was hospitalized, including previously healthy young adults with only mild influenza-like illnesses. Here we report the detailed clinical, virological and immunological characterization of the first five patients assessed at our institution, from the day of diagnosis until convalescence.

Materials and Methods

Study population and assessment

The first five patients (P1-P5) with COVID-19 confirmed by real-time reverse transcriptase polymerase chain reaction (rtRT-PCR) and quarantined at HUG were included in this single-center prospective cohort. These patients were screened for SARS-CoV-2 according to the national guidelines in place at the time, which recommended screening travelers returning from Italy and reporting respiratory and/or flulike symptoms. Ethical approval was waived by the local ethics committee (BASEC Req-2020-00143); written informed consent for sample collection and coded data gathering was obtained from each patient. Clinical characteristics were described according to the Severe Emerging Infections clinical protocol of the International Severe Acute Respiratory and Emerging Infection Consortium [15], and disease severity was assessed according to WHO's classification, where mild illness corresponds to mild symptoms without pneumonia [16]. If the patient agreed, we collected daily nasopharyngeal, oropharyngeal, conjunctival, sweat and anal swabs during hospitalization, as well as saliva, urine, and stool samples (see Supplementary methods). Plasma and serum were collected daily during hospitalization and at days 14 $\pm$ 2 and 28 $\pm$ 7 POS following discharge for viral load, antibody and cytokine quantification. Whole blood samples were used to isolate peripheral blood mononuclear cells (PBMC) to assess cellular responses.

Virological assessment

Quantitative real-time RT-PCR was performed on all clinical samples. RNA was extracted using the NucliSens eMAG extraction (BioMérieux, France) and quantified with the Charité rtRT-PCR protocol [17] using *in vitro* transcribed RNA for quantification (European Virus Archive) [18]. Screening for viral co-infections was performed via a large in-house panel of rt(RT-)PCR (see supplement). Viral culture was performed on VeroE6 cells as previously described [19]. Positive isolation of SARS-CoV-2 was confirmed upon presence of cytopathic effect (CPE) and an increase in viral RNA between two consecutive supernatant samples. Nasopharyngeal swabs (NPS) from P1 to P4 were tested by high-throughput sequencing (HTS) analysis in the context of SARS-CoV-2 viral genome epidemiological surveillance in Switzerland. Each sample was treated as previously published (see supplement) [20].

Measurement of inflammatory markers and blood cell phenotyping

Concentrations of 24 markers (see supplement) were measured in cryopreserved plasma using a Luminex assay (Magnetic Luminex assay, R&D Systems) according to the supplier's instructions. For data points below the detection limit, a value of 50% of the last standard dilution value was assumed.

For phenotyping of blood cells, cryopreserved PBMCs were thawed, counted and divided to perform T-cell and monocyte phenotyping. T cells were stained in PBS with LIVE/DEAD™ Stain Kit to exclude dead cells, anti-CD3, -CD4, -CD8, -CD38 and anti-HLA-DR antibodies and were then fixed and permeabilized. Anti-Granzyme B and anti-Ki67 antibodies were used for intracellular staining. For phenotyping of monocytes, cells were stained with FcR binding inhibitor, anti-CD3, -HLA-DR, -CD40, -CD123, -CD169, -CD20, -CCR2, -CD14, -CD16, -CD86, -CD163 and anti-CCR7 antibodies. All data were acquired the same day on a Fortessa II cytometer (BD Biosciences) and analyzed using FlowJo software (V10, Tree Star).

Antibody assays

S1 domain-specific IgG and IgA antibody response was measured using a commercially available kit (Euroimmun AG, Lübeck, Germany, #EI 2606-9601 G and EI 2606-9601 A) according to the manufacturer's instructions. To detect antibody against the complete S protein, ELISA plates were coated with a purified trimerized S protein kindly provided by the Ecole polytechnique fédérale de Lausanne (EPFL). IgG, IgA and IgM antibody titers were determined using a SARS-CoV-2 complete spike (S) protein-based rIFA [21, 22]. Neutralizing antibodies were quantified on VeroE6 cells infected with a VSV-based SARS-CoV-2 pseudotype expressing a 19-amino-acid, C-terminal truncated spike protein [23-25] (NCBI Reference sequence: NC_045512.2) with serially diluted sera. VeroE6 cells were infected with the virus-serum-mixture, and GFP positive infected cells were counted to assess titers [21]. Details can be found in the supplement.

Results

Clinical characteristics

Baseline demographic and clinical characteristics of the patients, all adult men, are shown in table 1. Four patients (P1-4) had only mild upper respiratory tract infections (URTI) and required no or only antipyretic

treatment. Their presentation was typical for the majority of COVID-19 patients (sore throat, cough, fever), including P1, who had almost no symptoms. The fifth patient (P5) had a severe illness with bilateral pneumonia; computed tomography (CT) revealed bilateral patchy infiltrates involving each pulmonary lobe and a left posterior basal consolidation 7 days POS (Sup Figure 1). On day 3 of hospitalization, he developed a maculopapular rash on the back and the trunk. His treatment included oxygen support, a 7-day course of antibiotics and lopinavir/ritonavir [26]. He recovered and was discharged after 10 days (day 15 POS). All laboratory parameters and in-depth clinical descriptions are available in supplementary tables 1-6.

Viral shedding patterns

SARS-CoV-2 was detected by rtRT-PCR in both the oropharyngeal (OPS) and nasopharyngeal swabs (NPS) of each patient, with high viral loads (VL) that declined over time (Figure 1A). Higher VL were detected in NPS than OPS (mean of 1.1×10^9 viral RNA copies/mL and 4.1×10^7 copies/mL, respectively) with a peak viral load of 2.5×10^{10} copies/mL for P2, sampled at the day of symptom onset. Lower viral loads in NPS, relative to viral loads of P1-4 on days 6-7 POS, were consistently observed for P5, for whom sampling started only on day 6 POS and covered the second week of illness.

Isolation of infectious virus was successful from both NPS and OPS during the first week of illness for the four mild cases, with the last positive virus isolation on day 7 for two patients (P1 and 3). The mean viral load in samples affording successful isolation was 1.2×10^9 copies/mL; the lowest RNA viral load in a sample from which a positive isolate could be obtained was 1.4×10^6 copies/mL. No infectious virus could be isolated from any sample from P5.

Prolonged RNA detection was observed in three patients, with persistent positive PCR results on days 14 (P5), 16 (P1) and 19 (P3) POS, albeit with low viral loads. RNA was also detected by PCR in saliva and stool specimens, with peak VLs of 7.8×10^6 and 8.6×10^5 copies/mL, respectively (Sup Figure S2). No virus was detected in other specimen types, and no RNAemia was observed in plasma. No virus isolation was attempted on non-respiratory samples.

Full genome sequences from P1-4 were found to cluster with sequences representative of the closest geographically related outbreak at that time, which was in Northern Italy. Molecular epidemiology is consistent with histories of travel to the region shortly before symptom onset for P1, P2 and P3 (Figure S3). A co-infection with adenovirus at a threshold cycle (Ct) value of 36 was detected in P1 on NPS collected at the time of his diagnosis. No other co-infections were detected in P2-P5.

Kinetics of the innate response

An increase in cytokine levels was observed in the first days POS (Figure 1B). Patients with mild symptoms had an increase in IFN- α , IFN- γ and IP-10 around day 2-3, which returned to baseline as symptoms resolved and VL decreased. IL-6, which has been associated with severe disease [27], was slightly more elevated at early time points, as were IL-1Ra and MCP-1. Their levels were similar to the ones observed in P5 when he was oxygen-dependent. Cytokine levels were generally lower in the patient with the mildest symptoms (P1). There were no significant changes in the other cytokines tested, such as TNF α , IL-1 β , IL-2 or IL-8 (not shown). CRP levels were much higher in P5 than in patients with mild disease (Figure 1C), suggesting that innate responses can be efficiently triggered in mild disease.

In line with the cytokine data, total numbers of monocytes and neutrophils were higher at early time points relative to later time points (Tables S2-S6). Because monocytes and macrophages have been shown to play an important role in pathogenesis [28], we performed a deeper phenotypic analysis of the circulating monocyte population by flow cytometry; it revealed a population of intermediate monocytes (CD14⁺ CD16^{high} cells), accounting for the majority of the monocytes detected in peripheral blood at days 2-3 POS (3% to 36% of cells from the live gate) (Figure 2A, B). This was seen in all patients irrespective of symptom severity, and decreased for one week POS in all mild patients with sequential samples. Their number was higher in P5 at the two time points tested. Intermediate monocytes expressed the highest levels of activation markers (CD86 and CD40) at 2-3 days POS, which was followed by the peak in the expression of differentiation and migration markers (HLA-DR, CD169, CD163, CCR-7) at one week POS (Figure 2C). In summary, we observed activation of innate responses in all patients, with a clear increase in type I interferon and pro-inflammatory cytokines, as well as significant increase in intermediate monocytes with activation, differentiation and migration patterns.

Antibody and cellular responses

Serum Ab titers against the spike protein (complete spike and S1 domain) were evaluated by ELISA and rIFA assay (Figure 3). Patients 1, 3, 4 and 5 seroconverted by two weeks POS, including P1 who had very mild and transient symptoms. For P2, no sample was available beyond day 7. P3 had no detectable IgA or IgM, and only low IgG levels (Figure 3A and B). Interestingly, this patient seroconverted only 3 weeks POS in S1-based ELISA (Figure 3A), but had already seroconverted after two weeks in complete S-based assays (rIFA and ELISA) (Figure 3A and B) and in neutralization assays (Figure 3C), indicating a potential role of S2-domain-specific antibodies in virus neutralization. P5 had the highest antibody levels and seroconverted earlier than patients with mild symptoms. Antibodies from all patients except P2, for whom samples from later time points were not available, were able to neutralize SARS-CoV-2 S-pseudotyped viruses; P5 again demonstrated the highest neutralizing antibody titers (Figure 3C). For P1 and P3 a late serum sample was obtained at 69 days POS. He had already showed a decline in IgG, IgA, IgM and neutralizing Ab titers (Figure 3A-C) while antibody levels of P3 declined only minimally (rIFA, S1 ELISA) or stayed the same (NT).

We measured the frequency of T lymphocytes and detected a marked reduction in total lymphocytes, particularly of CD8⁺ T cells, in P5 (Figure 4A, B). We further characterized the T-cell phenotype in terms of activation (expression of markers CD38 and HLA-DR), proliferation (Ki-67) of CD4 and CD8 T cells, and the expression of Granzyme B for CD8 T cells (Figure 4C, D). The highest frequency of activated CD8 T cells was detected in P5, with very few proliferating cells (Figure 4C). Although the frequency of activated CD8 T cells was lower in patients with mild symptoms, activated CD8 T cells expressed Granzyme B in all patients. For CD4 T cells, the frequency of activated cells was higher in P5 (CD38+HLA-DR⁺ CD4 T cells 2.8%) than in healthy individuals (mean 0.49%), and even in patients with mild symptoms (CD38+HLA-DR⁺ CD4 T cells <1.35%). Activated CD4 T cells were proliferating in all infected patients (Figure 4D). Altogether, the detection of activated and proliferative T cells in all patients suggests that even patients with mild disease are able to mount a T-cell-mediated immune response to SARS-CoV-2.

Discussion

We report the kinetics of viral load and immune responses in the first five COVID-19 patients hospitalized in our institution presenting with mild (P1-4) and severe (P5) disease. The most striking finding was a robust innate response in patients with mild symptoms characterized by early activation of monocytes. We also found prolonged viral RNA detection and measurable SARS-CoV-2 specific cellular and Ab responses despite the paucity of symptoms.

We documented high VL in the upper respiratory tract at diagnosis and the presence of infectious virus in both NPS and OPS, in samples taken hours POS in patients presenting with mild illness. Similar results have been documented in the pre-symptomatic phase [29] and can partly explain the high transmissibility of COVID-19. In all patients with mild disease, infectious virus could be isolated several days after symptom onset, up to day 7. Notably, symptoms had already waned for 5 days before the last successful isolation of infectious virus P1. We could not isolate SARS-CoV-2 in clinical specimens containing less than $1.4E6$ viral RNA copies/ml, in line with other reports [22]. Interestingly, no virus could be isolated from the NPS during the second week of illness, in the patient with the severe disease, possibly indicating antibody-mediated viral neutralization at that time. Except in stools and saliva, viral RNA was observed inconsistently and at low levels in other body fluids. This suggests that these fluids are not a major source of transmission. While patients with mild symptoms tend to have more limited shedding [6], prolonged RNA detection has also been reported by others [30]. In our study, no infectious virus could be retrieved from such samples, arguing for lingering remnant RNA rather than for active replication. While there is a need to confirm these findings in larger cohorts, they provide important information for discharge criteria and public-health decisions regarding isolation. Our data on isolation of infectious virus support most recommendations currently in effect, which advise isolation for at least 10 days POS for infection control, even in patients with very brief symptom durations.

Monocytes and macrophages play a critical role in the immunopathology of COVID-19 [28]. An increased number of cytokine-producing CD14⁺CD16⁺ monocytes and activated macrophages are seen in the blood and broncho-alveolar lavages of severe patients, respectively [31-33]. Zhou et al showed that increases in activated intermediated monocytes were mainly seen in intensive-care-unit (ICU) patients as opposed to non-ICU patients [34]. An interesting observation is that the rapid and drastic impact of SARS-CoV-2 infection on circulating monocytes in patients with very mild symptoms has a profile that is similar to what

is reported by Zhou and colleagues in ICU patients. The new observation could be due to the fact that our study captured very early responses. The rapid mobilization of monocytes is indicative of a robust local antiviral response. In patients without complications, this early mobilization of monocytes is not sustained and rapidly declines to baseline one-week POS. This monocyte signature is not unique to SARS-CoV-2: it has been described for dengue fever [35, 36] and other viral diseases [10, 37, 38].

In our study, all patients with mild symptoms, and with samples available from day 7 POS or later, mounted adaptive immune responses leading to neutralizing Ab. The question of the durability of the response and its quality over time remains open. As observed for P1 but not for P3, Ab titers including neutralizing Abs may rapidly decline in some non- or pauci-symptomatic COVID-19 patients. Experimental studies showed that immunity against reinfection by other human CoVs wanes over a few months, enabling reinfection within the first year after acute disease [39]. Low levels of non-neutralizing Ab may enhance disease severity at time of re-exposure [40], through an Ab-mediated mechanism described for other viruses. This could have important implications for both the clinical severity of repeat exposure and vaccination strategies eliciting more binding than neutralizing antibodies [41].

Our study has limitations. Although we were able to perform a comprehensive analysis of the immune response and viral shedding, the description is limited to five patients (with early time points missing for P5, and later time points missing for P2) and our interpretation of the association between viral load, innate and adaptive responses in patients with mild COVID-19 requires confirmation with a larger sample size. Finally, we were unable to follow all patients for late time points and cannot reach a conclusion about the durability of SARS-CoV-2 specific immunity according to disease pattern.

Conclusion

We provide a comprehensive immunological and virological profile of the first five patients diagnosed in our institution. Four had only mild and/or very transient symptoms and none received immunomodulatory treatments. Importantly we found that in both patients with mild symptoms and prolonged high viral loads, as well as one with severe disease, no virus could be isolated after the first week of illness. Even in patients with mild symptoms, we found a robust innate response characterized by the mobilization of activated monocytes in the first days of infection, associated with high viral loads and the induction of

286 interferon-dependent circulating cytokine responses. All patients mounted SARS-CoV-2 specific adaptive
287 responses including neutralizing antibodies.

Table legend:

Table 1: Main characteristics of the patients

RA: room air

*: during hospitalization

**: self-measured, at home, before hospitalization

Figure legends:

Figure 1. Kinetics of viral load and inflammatory markers

(A) Viral kinetics of nasopharyngeal (NPS) and oropharyngeal swab (OPS) samples. Plain logo: isolation of infectious virus in cell culture. Empty logo: infectious virus could not be isolated in cell culture. In grey: sample not available for virus isolation

(B) Cytokine and chemokines dynamics. Individual concentrations in pg/mL for each marker were plotted at different days POS for each patient. The dotted line represents the limit of detection for each marker. Samples with undetectable concentrations were arbitrarily given a value of 50% of the last standard dilution value.

(C) C-reactive protein (CRP) dynamics. Concentration in mg/L was plotted at different days POS for each patient.

Figure 2. Early increase in intermediate monocytes after Sars-CoV-2 infection.

(A) Gating strategy for the identification different monocytes subsets: classical monocytes (CM), intermediate monocytes (IM), non-classical monocytes (NCM) by flow cytometry after gating out dead cells and lineage (CD3, CD20) cells, and gating on HLA-DR+ cells. Early time points flow cytometry counterplots from P1 to P5 as well as a healthy control (HC) are shown.

(B) Percentage of CM, IM and NCM calculated from the lymphocyte live gate for each patient at different days POS. The dotted line represents one healthy donor.

(C) Geometric mean (GM) MFI value for different activation and migration markers in Intermediate Monocytes. The dotted line in red shows the mean of the isotype controls for each marker.

Figure 3. Antibody response to SARS-CoV-2

(A) IgG and IgA antibody kinetics for P1-5 using ELISA assays with either SARS-CoV-2 full S (only IgG, left graph) or S1-domain (IgG and IgA, middle and right graph) as antigen. For Full S ELISA endpoint titers were determined (starting dilution 1:100) whereas for S1-based ELISA the ratio of sample/calibrator was measured (dilution 1:100).

(B) Antibody kinetics using a recombinant full S-based immunofluorescence assay (rIFA) for IgG, IgM and IgA isotypes using starting dilution of 1:40 (IgG and IgA) or 1:10 (IgM). The left-panel shows representative rIFA staining patterns for IgG and IgM for two patients and a negative control serum.

(C) Kinetics of neutralizing antibody endpoint titers using a pseudotyped VSV neutralization assay (starting dilution 1:10).

Figure: 4 Kinetics of T-cell immune responses.

(A) Graphs show the frequency of total lymphocytes and of CD8 T cells.

B) The ratio of CD4/CD8 T cells was determined by flow cytometry as the ratio of the frequencies of CD4 and CD8 T cells (percentage of CD3 T cells)

(C) Representative flow plots are shown for CD8 T cell activation markers CD38 and HLA-DR. Histograms are shown for the expression of Ki67 (middle) and Granzyme B (lower) of activated (blue) and naive CD8 T cells (gray, gated on CD45RA⁺ CCR7⁺ CD8 T cells). The summary graph depicts the kinetics of HLA-DR + CD38⁺ CD8 T cells at different time points after symptoms onset. The bold dotted line is the mean of three healthy controls with its range (thin dotted line); “ ° ” identifies the time points that are shown as flow plots.

(D) Similar to C, representation of flow plots HLA-DR+CD38⁺ CD4 T cells (red), expressing the proliferation marker Ki67, with summarized data in the right graph.

Author Contributions: PV, IE, LK, and CE designed the study. PV, AC, DLV, MS and FJ collected clinical data and samples. FP, GT and IE conducted the virological analysis. SC and FL performed HTS analysis. CE, BM, PAM, SL, AMD and CAS conducted immunological analysis. PV, BM, CE, SC, AMD and IE contributed to the writing of the manuscript. All authors critically reviewed the manuscript and

accepted the final version.

Funding: This work was supported by Geneva University, Faculty of Medicine. The funder had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Acknowledgements: We thank Erik Boehm for editorial assistance, Sabine Yerly and Manel Essaidi-Laziosi for technical assistance, Angela Huttner for her meaningful insights and to colleagues at the protein core facility at the Ecole Polytechnique Fédérale de Lausanne for providing the complete S protein. We are also grateful to the patients who have agreed to participate in this study.

Conflict of interest: The authors declare no conflict of interest.

Table 1: Main characteristics of the patients

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age range	20-29	30-39	50-59	20-29	60-69
Sex	Male	Male	Male	Male	Male
Co-morbidities	None	None	None relevant for SARS-CoV-2 infection	None	None relevant for SARS-CoV-2 infection
Duration of Illness (days)	1	5	6	9	16
Maximal temperature (°C) *	38	38.4	38.5	39	37.3
Oxygene Saturation (RA/with oxygen (FiO2))	99% AA	99% AA	99% AA	100% AA	92% (32%)
Symptoms	Fever, rhinorrhea, headache	Fever, odynodysphagia, dry cough, headache	Fever, odynodysphagia, dry cough, chest pain	Fever, fatigue, dry cough	Fever**, fatigue, productive cough, skin rash
Diagnostic	Upper Respiratory Tract Infection	Upper Respiratory Tract Infection	Upper Respiratory Tract Infection	Upper Respiratory Tract Infection	Severe bilateral pneumonia
Treatment	None	Paracetamol	Alfuzosine, Paracetamol	Ibuprofen, Paracetamol, Enoxaparin	Co-amoxicilline + Clarythromycine, Piperacillin/Tazobactam, Lopinavir/ritonavir, Folic acid, Enoxaparin

Figure 1

Figure 2

Figure 3

Figure 3

A

B

C

Figure 4

References

1. Zhou, P., et al., *A pneumonia outbreak associated with a new coronavirus of probable bat origin*. Nature, 2020. **579**(7798): p. 270-273.
2. WHO. *Novel Coronavirus 2019 Situation Reports*. 2020 05-27-2020]; Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>.
3. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China*. The Lancet, 2020. **395**(10223): p. 497-506.
4. Vetter, P., et al., *Clinical features of covid-19*. BMJ, 2020. **369**: p. m1470.
5. Wu, Z. and J.M. McGoogan, *Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention*. JAMA, 2020.
6. Liu, Y., et al., *Viral dynamics in mild and severe cases of COVID-19*. Lancet Infect Dis, 2020. **20**(6): p. 656-657.
7. Chen, G., et al., *Clinical and immunological features of severe and moderate coronavirus disease 2019*. The Journal of Clinical Investigation, 2020. **130**(5): p. 2620-2629.
8. Liu, F., et al., *Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19*. J Clin Virol, 2020. **127**: p. 104370.
9. Wynants, L., et al., *Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal*. BMJ, 2020. **369**: p. m1328.
10. Zhang, J.Y., et al., *Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B*. PLoS One, 2011. **6**(3): p. e17484.
11. Hadjadj, J., et al., *Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients*. medRxiv, 2020: p. 2020.04.19.20068015.
12. Grifoni, A., et al., *Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals*. Cell, 2020.
13. Thevarajan, I., et al., *Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19*. Nature Medicine, 2020. **26**(4): p. 453-455.
14. Weiskopf, D., et al., *Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome*. medRxiv, 2020: p. 2020.04.11.20062349.
15. ISARIC, *ACUTE RESPIRATORY INFECTION CLINICAL CHARACTERISATION DATA TOOL*. 2020.
16. (WHO), W.H.O.T., *Clinical management of COVID-19*. (<https://www.who.int/publications/i/item/clinical-management-of-covid-19> Accessed Jun, 6, 2020).
17. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR*. Eurosurveillance, 2020. **25**(3): p. 2000045.
18. project, E. *European Virus Archive - GLOBAL*. 2020; Available from: <https://www.european-virus-archive.com/>.
19. L'Huillier, A., et al., *Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents*. medRxiv 2020.04.27.20076778; doi: <https://doi.org/10.1101/2020.04.27.20076778>, Accessed Jun 9, 2020, 2020.
20. Petty, T.J., et al., *Comprehensive human virus screening using high-throughput sequencing with a user-friendly representation of bioinformatics analysis: a pilot study*. J Clin Microbiol, 2014. **52**(9): p. 3351-61.
21. Meyer, B., et al., *Validation of a commercially available SARS-CoV-2 serological Immunoassay*. medRxiv, 2020: p. 2020.05.02.20080879.

22. Wölfel, R., et al., *Virological assessment of hospitalized patients with COVID-2019*. Nature, 2020. **581**(7809): p. 465-469.
23. Berger Rentsch, M. and G. Zimmer, *A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon*. PLoS One, 2011. **6**(10): p. e25858.
24. Torriani, G., et al., *Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion*. J Virol, 2019. **93**(6).
25. Fukushi, S., et al., *Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein*. J Gen Virol, 2005. **86**(Pt 8): p. 2269-2274.
26. Cao, B., et al., *A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19*. N Engl J Med, 2020. **382**(19): p. 1787-1799.
27. Aziz, M., R. Fatima, and R. Assaly, *Elevated interleukin-6 and severe COVID-19: A meta-analysis*. J Med Virol, 2020.
28. Merad, M. and J.C. Martin, *Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages*. Nature Reviews Immunology, 2020. **20**(6): p. 355-362.
29. He, X., et al., *Temporal dynamics in viral shedding and transmissibility of COVID-19*. Nat Med, 2020. **26**(5): p. 672-675.
30. Danis, K., et al., *Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020*. Clinical Infectious Diseases, 2020.
31. Wen, W., et al., *Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing*. Cell Discovery, 2020. **6**(1): p. 31.
32. Zhang, D., et al., *COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome*. medRxiv, 2020: p. 2020.03.24.20042655.
33. Liao, M., et al., *Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19*. Nature Medicine, 2020.
34. Zhou, Y., et al., *Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients*. National Science Review, 2020.
35. Azeredo, E.L., et al., *Differential regulation of toll-like receptor-2, toll-like receptor-4, CD16 and human leucocyte antigen-DR on peripheral blood monocytes during mild and severe dengue fever*. Immunology, 2010. **130**(2): p. 202-16.
36. Kwissa, M., et al., *Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation*. Cell Host Microbe, 2014. **16**(1): p. 115-27.
37. Chen, P., et al., *Perturbations of Monocyte Subsets and Their Association with T Helper Cell Differentiation in Acute and Chronic HIV-1-Infected Patients*. Front Immunol, 2017. **8**: p. 272.
38. Rodríguez-Muñoz, Y., et al., *Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C*. Aliment Pharmacol Ther, 2011. **34**(8): p. 960-71.
39. Galanti, M. and J. Shaman, *Direct observation of repeated infections with endemic coronaviruses*. medRxiv, 2020: p. 2020.04.27.20082032.
40. Iwasaki, A. and Y. Yang, *The potential danger of suboptimal antibody responses in COVID-19*. Nature Reviews Immunology, 2020. **20**(6): p. 339-341.
41. Lambert, P.-H., et al., *Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines*. Vaccine, 2020.

Supplementary appendix:

Supplementary Methods

Sample collection

We collected daily nasopharyngeal, oropharyngeal, conjunctival, sweat and anal swabs as well as saliva, urine and stool samples if the patient agreed, using 3mL universal transport medium tubes (Copan, Brescia, Italy). Urine and stools were collected daily (when available) in plastic tubes without additives. Plasma and serum were collected in EDTA and in SST II plastic tubes, daily during hospitalization and at days 14 +/- 2 and 28 +/- 7 post onset of symptoms (POS) following discharge for viral load, antibody (Ab) and cytokine quantification. Cell-preparation tubes (CPT) with sodium citrate were used for collection of whole blood and separation of peripheral blood mononuclear cells (PBMC) to assess cellular responses.

Assessment of infectious viruses

VeroE6 cells were seeded at a density of 8×10^4 cells/well in a 24-well plate and inoculated with 200 μ L of viral transport medium the following day. Cells were inoculated for 1h at 37°C, then inoculum was removed, cells were washed 1x with PBS and then regular cell growth medium containing 10% FCS was added. Cells were observed on days 2, 4, and 6 for the presence of CPE by light microscopy. Supernatant was harvested upon the first observation of a CPE, or, if no CPE was observed, at the end of the experiment on day 6.

Testing for viral co-infections

Nasopharyngeal swabs were screened by acid nucleic detection for the presence of influenza A and B virus, respiratory syncytial virus (RSV) A and B, parainfluenza 1 to 4, human metapneumovirus, rhinoviruses, enteroviruses, bocavirus 1, adenovirus and human coronaviruses 229E, OC43, HKU1 and NL63 as previously described. (1)

High-throughput sequencing

110 μ L of NPS were centrifuged at $10,000 \times g$ for 10 min. One-hundred μ L of cell-free supernatant were treated with 20 U of Turbo DNase (Ambion, Rotkreuz, Switzerland). Viral nucleic acids were extracted

with TRIzol (Invitrogen, Carlsbad, CA, USA) and resuspended in 10 µl of RNase-free water. Ribosomal RNA was removed using the Ribo-Zero Gold depletion kit (Illumina, San Diego, US). Thereafter, libraries were generated using the TruSeq total RNA preparation protocol (Illumina) with dual indexing and loaded on the HiSeq 4000 platform (Illumina) using the 2x100-bp protocol. Raw data were analysed as follows: duplicate reads were removed using cd-hit (v4.6.8). Then reads were then trimmed to remove low-quality and adapter sequences using Trimmomatic (v0.33). Next reads were mapped against the reference sequences MN908947.3 using the SNAP nucleotide aligner program. (2) The four hCoV-19 complete sequences hCoV-19/Switzerland/GE3895/2020 (P1), hCoV-19/Switzerland/GE9586/2020 (P2), hCoV-19/Switzerland/GE3121/2020 (P3), and hCoV-19/Switzerland/GE0199/2020 (P4) were all submitted and made available via GISAID.

Assessment of innate immunity

The following list of markers were tested in Luminex : CD40L, GM-CSF, Granzyme B, IFN-α, IFN-γ, IL1α, IL1-b, IL1R-α, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL17A, IL-33, IP-10, MCP-1, MIP-1α, MIP-1b, PD-L1, TNF-α. The mean fluorescence intensity of each marker was read on the Bio-Plex 200 array reader (Bio-Rad Laboratories) using the Luminex xMAP Technology (Luminex Corporation). Sample concentrations were calculated using a five-parameter logistic regression curve (Bio-Plex Manager 6.0)

References for reagents used for cell phenotyping

LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit (Life Technologies), Fixation/Permeabilization kit (Invitrogen 00-8333-56), anti-CD3 (clone SK7 BioLegend), anti-CD4 (clone RPA-T4, BD), anti-CD8 (clone SK1, BD), CD38 (clone HIT2, BioLegend), HLA-DR (clone L243, BioLegend), Granzyme B (clone GB11, BD), Ki67 (clone B56, BD), FcR binding inhibitor (14-9161-73, Invitrogen), anti-CD3 (clone SP34-2, BD), HLA-DR (clone G46-6, BD), CD40 (clone 5C3, BD), CD123 (clone 7G3, BD), CD169 (clone 7-239, Biolegend), CD20 (clone, BD), CCR2 (clone REA264, Miltenyi), CD14 (clone M5E2, BD), CD16 (clone 3G8, BD), CD86 (clone IT2.2 Biolegend), CD163 (clone GHI/61, BD), CCR7 (clone 3D12, BD)

Complete S protein-based ELISA

We coated 37.5ng/well of a purified trimerized S protein diluted in 0.1M sodium carbonate buffer pH 9.6 O/N at 4°C. Plates were blocked (5% milk PBS-T) and 100 ul of 2-fold serially diluted sera (range 100-12,800) were applied to wells with and without antigen. After incubation (1h at 37°C) and washing (3x 1min with PBS-T) 100ul HRP-conjugated anti-human IgG (Jackson ImmunoResearch, #109-036-098) diluted 1:16,000 was added. After incubation plates were washed and 100ul of TMB substrate (Invitrogen) was added for 10min. Reaction was stopped by 100ul of 1N HCl and plates were read at 450nm. OD450 values of blank wells were subtracted from values of antigen containing wells for each serum and each dilution. The cut-off to determine the ELISA titer was set at 0.29 OD450, just before OD values reach the plateau phase.

rIFA assay

Briefly, pCG1 vector expressing SARS-CoV-2 S protein (kindly provided by M. Hoffmann and S. Pöhlmann, DPZ Göttingen) was transfected into Vero B4 cells using Fugene HD (Promega #E2311), spotted on multitest microscopy slides (DUNN Labortechnik GmbH #40-412-05) and fixed with ice-cold Acetone/Methanol (1:1). To perform the rIFA sera were inactivated for 30min at 56°C. To remove IgG antibodies for determination of IgM antibody titres, sera were treated with Eurosorb reagent (Euroimmun AG #1270-0145). Slides were rehydrated in PBS-T for 5min and blocked (5% milk PBS-T) for 30min at RT. Sera were diluted using a starting dilution of 1:40 for IgG/IgA and 1:10 for IgM and 30µl were applied to each spot. After incubation (1h, 37°C) slides were washed (3x1min, PBS-T) and 25µl of Alexa488-conjugated goat anti-human-IgG, -IgM. or -IgA antibody (Jackson ImmunoResearch #109-036-098, #, #) diluted 1:200 in PBS was applied. After incubation (37°C, 45min), slides were washed as before and briefly rinsed with dH₂O before mounting with glycerol.

Quantification of neutralizing antibodies

VeroE6 cells were seeded in 96-well plates at 2×10^4 cells per well and grown into confluent monolayer overnight. Sera from patients were inactivated at 56°C for 30 minutes and diluted from 1:5 to 1:1280 in DMEM 2% FBS. VSV-based SARS-CoV-2 pseudotypes (3, 4) expressing a 19 amino acids C-terminal truncated spike protein (5) (NCBI Reference sequence: NC_045512.2) were diluted in DMEM 2% FCS in

order to have MOI=0.01 per well and added on top of serum dilutions (final serum dilutions obtained were from 1:10 to 1:2560). The virus-serum mix was incubated at 37°C, for 2h. Vero E6 were then infected with 100µl of virus-serum mixtures. After incubation at 37°C for 1.5h, cells were washed once with 1X PBS and DMEM 10% FBS was added. After 16-20h of incubation at 37°C, 5% CO₂ cells were fixed with 4% formaldehyde solution for 15min at 37°C and nuclei stained with 1µg/ml DAPI solution. GFP positive infected cells were counted with ImageXpress® Micro Widefield High Content Screening System (Molecular Devices) and data analyzed with MetaXpress 5.1.0.41 software.

Supplementary material

Supplementary Table 1: Detailed characteristics of the patients

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Smoking history	Occasional smoker	Current smoker	No	No	No
Epidemiological exposure	Travelled to country with local transmission	Travelled to country with local transmission	Travelled to country with local transmission	Relative of patient 1	Unclear; met asymptomatic relatives back from countries with local transmission 15 and 12 days before symptoms onset
Other	<i>Chlamydomytila/Myco plasma</i> (Throat swab) PCR neg	Blood culture on admission: no pathogen growth	Urine culture: no pathogen growth	Blood culture on admission: no pathogen growth	Blood culture on admission: no pathogen growth Urinary Legionella pneumophila and Streptococcus pneumoniae Ag negative Chlamydomytila/Myco plasma (Throat swab) PCR neg Urine culture: no pathogen growth Skin biopsy : suprabasal acantholysis, ballooned multinuclear cells, lymphohistiocytic infiltrate of the dermis
Viral co-infection	Adenovirus	None detected	None detected	None detected	None detected
Imaging					
Chest X-ray	N/A	N/A	N/A	No infiltrates	Bilateral patchy infiltrates
CT-Scan	N/A	N/A	N/A	N/A	Left postero-basal consolidation, bilateral patchy infiltrates

Legend: CRP: C Reactive Protein; PCT: procalcitonin; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = gamma-glutamyl transferase

635 Table S2: Patient 1's laboratory parameters during hospitalization

Parameter	Units	Normal range Min/max	D15	D6	D5	D4	D3	D2	D 1
Erythrocytes	T/l	4.4 - 6	5.29	5.36	5.47	5.56	5.78	5.55	5.39
Hemoglobine	g/l	140 - 180	165	165	170	171	179	173	167
Hematocrite	%	40 - 52	46.9	46.9	47.4	48.1	50.5	48.9	46.8
MCV	fl	82 - 98	88.7	87.5	86.7	86.5	87.4	88.1	86.8
MCH	pg	26 - 34	31.2	30.8	31.1	30.8	31	31.2	31
MCHC	g/l	320 - 360	352	352	359	356	354	354	357
Leucocytes	G/l	4 - 11	11.5	7.3	7.8	8.8	8.1	6.6	7
White blood cell count									
neutrophiles	%	33 - 80		42.3	45.3	48.5	44.8		39.7
segmented neutrophiles	%	33 - 75	65						
non segmented neutrophiles	%	0 - 5	0						
eosinophiles	%	0 - 5	0	4.5	3.8	4.6	4		1.6
basophiles	%	0 - 2	1	0.8	0.5	0.5	0.5		0.9
monocytes	%	0 - 9	10	16	15.6	14.6	14.3		23.1
lymphocytes	%	15 - 60	23	36.4	34.8	31.8	36.4		34.7
plasmocytes	%	0 - 0	1						
neutrophiles-absolute number	G/l	1.5 - 8		3.09	3.53	4.27	3.63		2.78
segmented neutrophiles- absolute number	G/l	1.5 - 7.5	7.48						
non segmented neutrophiles - absolute number	G/l	0 - 0.5	0						
lymphocytes-absolute number	G/l	1 - 4.5	2.65	2.66	2.71	2.8	2.95		2.43
Thrombocytes									
thrombocytes	G/l	150 - 350	277	208	216	237	227	219	230
MPV	fl	8 - 12	11.3	11.2	11.1	10.9	10.8	10.8	11.3
C reactive protein	mg/l	0 - 10		3.4	3	1.7	1.4	2.4	7.1
sodium	mmol/l	136 - 144		141	139	138	138	139	139
potassium	mmol/l	3.6 - 4.6		4.4	4.1	4.3	4.2	4.3	3.7
urea	mmol/l	3.2 - 7.5		5	5.2	5.4	5.9	6.5	4.9
creatinine	μmol/l	62 - 106	101	100	98	93	103	111	105
eGFR (CKD-EPI)	ml/min/ 1.73m ²	> 60	87	88	90	96	85	78	83
AST	U/l	14 - 50	32	25	29	37	46	54	50
ALT	U/l	12 - 50	41	43	49	58	71	75	66
Alcaline phosphatase	U/l	25 - 102		98	98	101	105	96	104
GGT	U/l	9 - 40		41		47	52	49	46
Total Bilirubin	μmol/l	7 - 25		9	13	14	10	6	7
Quick	%	> 70		77	74				75
INR				1.14	1.15				1.15
PTT	sec	26 - 37			28				27.8
fibrinogène	g/l	1.5 - 3.5			2.9				2.7

636
637
638

639 Table S3: Patient 2's laboratory parameters during hospitalization

Parameter	Units	Normal range Min/max	D7	D6	D5	D4	D3	D2	D1
Erythrocytes	T/l	4.4 - 6	5.48	5.45	5.4	5.52	5.38	5.51	5.64
Hemoglobine	g/l	140 - 180	158	158	157	160	157	159	167
Hematocrite	%	40 - 52	45.5	46	45.4	46.2	44.8	45.7	47.2
MCV	fl	82 - 98	83	84.4	84.1	83.7	83.3	82.9	83.7
MCH	pg	26 - 34	28.8	29	29.1	29	29.2	28.9	29.6
MCHC	g/l	320 - 360	347	343	346	346	350	348	354
Leucocytes	G/l	4 - 11	7.8	6.6	5.9	7.4	10.2	11.5	10.9
White blood cell count									
neutrophiles	%	33 - 80	44.5	41.4	32.9	44.9	60.9	67.9	69
segmented neutrophiles	%	33 - 75	2.4	1.8	2.2	1.1	0.3	2.7	0.1
non segmented neutrophiles	%	0 - 5	0.5	0.5	0.5	0.3	0.2	0.3	0.4
eosinophiles	%	0 - 5	9.1	10.3	11.1	11.4	10.2	10.5	12.2
basophiles	%	0 - 2	43.5	46	53.3	42.3	28.4	18.6	18.3
monocytes	%	0 - 9	3.47	2.73	1.94	3.32	6.21	7.81	7.52
lymphocytes	%	15 - 60	3.39	3.04	3.14	3.13	2.9	2.14	1.99
neutrophiles-absolute number	G/l	1.5 - 8	214	204	189	176	131	194	244
segmented neutrophiles- absolute number	G/l	1.5 - 7.5	10.4	10.3	10.5	10.4	11.1	10.1	10.2
non segmented neutrophiles - absolute number	G/l	0 - 0.5	0						
lymphocytes-absolute number	G/l	1 - 4.5	2.65	2.66	2.71	2.8	2.95		2.43
Thrombocytes									
thrombocytes	G/l	150 - 350	277	208	216	237	227	219	230
MPV	fl	8 - 12	11.3	11.2	11.1	10.9	10.8	10.8	11.3
C reactive protein	mg/l	0 - 10	3.8	4.3	7.3	11	14.7	14	6.3
sodium	mmol/l	136 - 144	139	140	139	140	136	135	137
potassium	mmol/l	3.6 - 4.6	4.1	4.4	4.2	4.1	3.8	3.6	3.9
urea	mmol/l	3.2 - 7.5	3.6	4.2	3.7	4.2	4.2	3.9	5.2
creatinine	μmol/l	62 - 106	83	93	99	89	94	108	105
eGFR (CKD-EPI)	ml/min/1.73m ²	> 60	109	95	88	100	93	79	82
AST	U/l	14 - 50	26	29	29	29	30	37	39
ALT	U/l	12 - 50	44	45	41	41	47	52	58
Alcaline phosphatase	U/l	25 - 102	38	40	38	38	38	43	44
GGT	U/l	9 - 40	91	92	90	92	97	102	105
Total Bilirubin	μmol/l	7 - 25	8	7	6	7	7	7	7
Quick	%	> 70	>100		>100				94
INR			1		1				1.03
PTT	sec	26 - 37	25.4						

640
641
642

643 Table S4: Patient 3's laboratory parameters during hospitalization

Parameter	Units	Normal range Min/max	D19	D9	D8	D7	D6	D5	D4	D3	D2
Erythrocytes	T/l	4.4 - 6	4.7	4.84	4.66	4.96	5.06	4.96	4.83	5.1	4.69
Hemoglobin	g/l	140 - 180	138	141	140	142	147	146	143	151	140
Hematocrite	%	40 - 52	38.2	39.6	38.2	40.1	41.3	41	40.3	42.1	38.9
MCV	fl	82 - 98	81.3	81.8	82	80.8	81.6	82.7	83.4	82.5	82.9
MCH	pg	26 - 34	29.4	29.1	30	28.6	29.1	29.4	29.6	29.6	29.9
MCHC	g/l	320 - 360	361	356	366	354	356	356	355	359	360
Leucocytes	G/l	4 - 11	4.6	2.9	3.5	2.8	3	2.5	2.2	2.7	2.8
White blood cell count											
neutrophils	%	33 - 80	54.5	48	47.8	47.3	42.3	43			48.8
segmented neutrophils	%	33 - 75							47	40	
non segmented neutrophils	%	0 - 5							0	8	
eosinophiles	%	0 - 5	1.5	2.4	2.3	2.5	2.6	2	2	1	0.7
basophiles	%	0 - 2	0.7	0.3	0.3	0.4	0.3	0.4	0	0	0.7
monocytes	%	0 - 9	10	11.3	9.9	10.2	10.6	10	3	8	17.8
lymphocytes	%	15 - 60	33.3	38	39.7	39.6	44.2	44.6	48	43	32
neutrophils-absolute number	G/l	1.5 - 8	2.51	1.39	1.67	1.32	1.27	1.08			1.37
segmented neutrophils- absolute number	G/l	1.5 - 7.5							1.03	1.08	
non segmented neutrophils - absolute number	G/l	0 - 0.5							0	0.22	
lymphocytes-absolute number	G/l	1 - 4.5	1.53	1.1	1.39	1.11	1.33	1.12	1.06	1.16	0.9
Thrombocytes											
thrombocytes	G/l	150 - 350	184	132	117	122	128	130	114	132	116
MPV	fl	8 - 12	10.6	11.1	10.7	10.4	10.3	10.8	10.8	10.5	11
C reactive protein	mg/l	0 - 10		1	1.1	1.3	1.9	2.7	4.5	9.6	13.7
sodium	mmol/l	136 - 144		139	139	140	142	141	141		143
potassium	mmol/l	3.6 - 4.6		4.2	4.4	4.3	4.3	4	4.3		4
urea	mmol/l	3.2 - 7.5	5.2	4.8	5.6	4.9	4.7	4.8	4.8	5.6	5.6
creatinine	μmol/l	62 - 106	98	82	87	72	76	76	75	85	82
eGFR (CKD-EPI)	ml/min/1.73m ²	> 60	75	92	86	100	98	98	98	89	92
AST	U/l	14 - 50	30	39	36	45	60	29	23	32	26
ALT	U/l	12 - 50	34	77	76	87	96	32	24	30	27
Alcaline phosphatase	U/l	25 - 102		59	50	47	50	51	56	60	56
GGT	U/l	9 - 40		33	33	33	37	28	18	19	18
Total Bilirubin	μmol/l	7 - 25		7	7	8	7	7	5	6	5
procalcitonine	μg/l	< 0.25								0.08	
Quick	%	> 70			>100						
INR					1						
PTT	sec	26 - 37			27.5					31.1	
fibrinogène	g/l	1.5 - 3.5								2.4	
D dimers	ng/ml	45 - 500								383	

644
645
646

647 Table S5: Patient 4's laboratory parameters during hospitalization

Parameter	Units	Normal range Min/max	D7	D6	D5	D4	D3	D2	D1
Erythrocytes	T/l	4.4 - 6	5.31	5.51	5.45	5.5	5.45	5.3	5.54
Hemoglobine	g/l	140 - 180	149	155	156	154	156	153	159
Hematocrite	%	40 - 52	43.4	44.8	44	44.4	45.1	44.1	45.9
MCV	fl	82 - 98	81.7	81.3	80.7	80.7	82.8	83.2	82.9
MCH	pg	26 - 34	28.1	28.1	28.6	28	28.6	28.9	28.7
MCHC	g/l	320 - 360	343	346	355	347	346	347	346
Leucocytes	G/l	4 - 11	3.9	3.5	3.7	4.1	4.7	5.9	6.6
White blood cell count									
neutrophiles	%	33 - 80	43.6	34.7	46.9	46	45	61.6	80.2
eosinophiles	%	0 - 5	1.3	1.4	0.5	0.2	0	2	0
basophiles	%	0 - 2	0.3	0.6	0	0.2	0.2	0.3	0.3
monocytes	%	0 - 9	9.3	11.6	12.9	12.7	14.7	13.7	12.5
lymphocytes	%	15 - 60	45.5	51.7	39.7	40.9	40.1	22.4	7
neutrophiles-absolute number	G/l	1.5 - 8	1.7	1.21	1.74	1.89	2.12	3.63	5.29
lymphocytes-absolute number	G/l	1 - 4.5	1.77	1.81	1.47	1.68	1.88	1.32	0.46
Thrombocytes	G/l	150 - 350	109	113	123	124	113	116	136
MPV	fl	8 - 12	11.5	11.5	11.3	11.6	11.6	10.8	11.1
C reactive protein	mg/l	0 - 10	1.3	1.1	1.3	1.4	2.1	5.7	7.7
sodium	mmol/l	136 - 144	139	137	140	138	138	140	140
potassium	mmol/l	3.6 - 4.6	3.9	3.8	4.1	3.7	3.8	3.7	3.5
urea	mmol/l	3.2 - 7.5	4.1	4.2	4.7	5.3	6	6.6	6.7
creatinine	μmol/l	62 - 106	94	93	92	94	101	110	95
eGFR (CKD-EPI)	ml/min/1.73m ²	> 60	97	99	100	97	89	81	96
lactate deshydrogénase	U/l	87 - 210							213
AST	U/l	14 - 50	25	19	22	23	21	23	20
ALT	U/l	12 - 50	26	25	27	26	26	32	31
Alcaline phosphatase	U/l	25 - 102	64	55	53	56	57	58	65
GGT	U/l	9 - 40	33	34	32	34	35	34	37
Total Bilirubin	μmol/l	7 - 25	12	9	10	9	9	7	7
procalcitonine	μg/l	< 0.25							
Quick	%	> 70		>100		99	86		81
INR				1		1	1.07		1.1
PTT	sec	26 - 37		25.4		29	27.7		27.2
fibrinogène	g/l	1.5 - 3.5					3.2		3.3

648
649
650

Table S6: Patient 5's laboratory parameters during hospitalization

Parameter	Units	Normal range	D15	D13	D12	D11	D10	D9	D8	D6
		Min/max								
érythrocytes	T/l	4.4 - 6	4.64	4.22	4.13		3.92	4.05	4.2	4.73
hémoglobine	g/l	140 - 180	126	119	118		113	115	115	132
hématocrite	%	40 - 52	39.2	35.6	34.9		33	34.5	35.7	40.1
MCV	fl	82 - 98	84.5	84.4	84.5		84.2	85.2	85	84.8
MCH	pg	26 - 34	27.2	28.2	28.6		28.8	28.4	27.4	27.9
MCHC	g/l	320 - 360	321	334	338		342	333	322	329
Réticulocytes										
réticulocytes	o/oo Ery	5 - 15			12.6					
réticulocytes-nb.abs	G/l	20 - 120			52.04					
HFR	%	0 - 1.5			8.7					
Ret-He	pg	28 - 35			29.3					
leucocytes	G/l	4 - 11	6	5.2	5.5		5.7	5.7	7	12
Répartition leucocytaire										
neutrophiles	%	33 - 80								92.6
neutrophiles segmentés	%	33 - 75	64	48	68		71	75		
neutrophiles non segmnt	%	0 - 5	2	2	0		3	2		
éosinophiles	%	0 - 5	1	9	6		3	2		0
basophiles	%	0 - 2	1	0	0		0	0		0.2
monocytes	%	0 - 9	4	16	16		12	6		3.4
lymphocytes	%	15 - 60	25	20	9		11	15		3.8
myélocytes	%	0 - 0	3	5	1					
cellules réparties			100	100	100		100	100		
neutrophiles-nb abs	G/l	1.5 - 8								11.11
neutro segmentes nb.abs	G/l	1.5 - 7.5	3.84	2.5	3.74		4.05	4.28		
neutro non seg.-nb.abs	G/l	0 - 0.5	0.12	0.1	0		0.17	0.11		
lymphocytes-nb.abs	G/l	1 - 4.5	1.5	1.04	0.5		0.63	0.86		0.46
Thrombocytes										
thrombocytes	G/l	150 - 350	489	419	352		284	262	235	222
MPV	fl	8 - 12		9	9.2	9.3	9.3	9.5	9.4	9.5
C reactive protein	mg/l	0 - 10		26.7	44	70.1	76.4	89.2	144.4	180.5
sodium	mmol/l	136 - 144		138	142	141	139	141	140	138
potassium	mmol/l	3.6 - 4.6		3.9	4	3.6	3.4	3.7	3.9	3.8
urea	mmol/l	3.2 - 7.5		3	3.2	2.8	2.5	3.3	4.5	4.3
creatinine	μmol/l	62 - 106		58	55	59	55	58	59	63
eGFR (CKD-EPI)	ml/min/1.73m ²	> 60		101	103	100	103	101	100	98
Troponine T ultra sensible	ng/l	< 14				5 [E]				
lactate deshydrogénase	U/l	87 - 210					191			
AST	U/l	14 - 50		44	39	33		30	26	24
ALT	U/l	12 - 50		45	37	29		23	16	16
Alcaline phosphatase	U/l	25 - 102		58	59	68		69	58	49
GGT	U/l	9 - 40		61	64	75		68	52	38
Total Bilirubin	μmol/l	7 - 25		5	6	18		9	8	9
procalcitonine	μg/l	< 0.25						0.19		
Quick	%	> 70						>100		>100
INR								1		1
PTT	sec	26 - 37						25.2		26.8
fibrinogène	g/l	1.5 - 3.5								8.4

Figure S1: CT-scan of patient 5 showing (A) bilateral patchy ground-glass opacities, mainly in the upper lobes, and (B) postero-basal consolidation, more marked on the left side.

Figure S2: viral load in saliva, stool, tears and urine

Figure S3: Phylogenetic tree constructed on the basis of SARS-CoV-2 complete genome sequences.

Legend:

- A) The Evolutionary analyses were conducted in MEGA X using the Maximum Likelihood method and Hasegawa-Kishino-Yano model. All sequences were downloaded from GISAID database (for more information refer to the [gisaid_hcov-19_acknowledgement_table](#) below). Scale bar indicates nucleotide substitutions per site.
- B) GISAID HCoV-19 acknowledgement table

677 A)
678

679 B)
680

We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu™ Database on which this research is based. The list is detailed below.
All submitters of data may be contacted directly via www.gisaid.org

Accession ID	Virus name	Location	Collection date	Originating lab	Submitting lab	Authors
EPI_ISL_402119	hCoV-19/Wuhan/IVDC-HB-01/2019	Asia / China / Hubei / Wuhan	2019-12-30	National Institute for Viral Disease Control and Prevention, China CDC	National Institute for Viral Disease Control and Prevention, China CDC	Wenjie Tan, Xiang Zhao, Wenling Wang, Xuejun Ma, Yongsheng Jiang, Roujian Li, Ji Wang, Weimin Zhou, Peihua Niu, Peipei Liu, Faxian Zhan, Wefeng Shi, Baoying Huang, Jun Liu, Li Zhao, Yao Meng, Xiaochou He, Fei Ye, Na Zhu, Yang Li, Jing Chen, Wentao Xu, George F. Gao, Guocheng Wu
EPI_ISL_404895	hCoV-19/USA/WA1/2020	North America / USA / Washington	2020-01-19	Providence Regional Medical Center	Division of Viral Diseases, Centers for Disease Control and Prevention	Queen K. Tao, Y. Li, Y. Paden, C.R. Lu, X. Zhang, J. Gerber, S.I. Lindstrom, S. Tong S.
EPI_ISL_406036	hCoV-19/USA/CA2/2020	North America / USA / California	2020-01-22	California Department of Public Health	Pathogen Discovery, Respiratory Viruses Branch, Division of Viral Diseases, Centers for Diseases Control and Prevention	Anna Uehara, Krista Queen, Ying Tao, Yan Li, Clinton R. Paden, Jing Zhang, Xiaoyan Lu, Brian Lynch, Senthil Kumar K. Sakthivel, Brett L. Whitaker, Shihai Kamili, Lijuan Wang, Janna R. Murray, Susan I. Gerber, Stephen Lindstrom, Suixiang Tong
EPI_ISL_406596	hCoV-19/France/IDF0372/2020	Europe / France / Ile-de-France / Paris	2020-01-23	Department of Infectious and Tropical Diseases, Bichat Claude Bernard Hospital, Paris	National Reference Center for Viruses of Respiratory Infections, Institut Pasteur, Paris	Milanie Albert, Marion Barbet, Sylvie Behilli, Meline Bizard, Angela Brisebarre, Flora Donati, Vincent Enouf, Maud Vanpeene, Sylvie van der Werf, Yacine Yacinegarani, Xavier Lecours
EPI_ISL_406862	hCoV-19/Germany/BavPat1/2020	Europe / Germany / Bavaria / Munich	2020-01-26	Charité Universitätsmedizin Berlin, Institute of Virology; Institut für Mikrobiologie der Bundeswehr, Munich	Charité Universitätsmedizin Berlin, Institute of Virology	Victor M. Corman, Julia Schneider, Talitha Veith, Barbara Muhlemann, Markus Antwerpen, Christian Drosten, Roman Wolfel
EPI_ISL_410546	hCoV-19/Italy/INMI1-cs/2020	Europe / Italy / Rome	2020-01-31	INMI Lazzaro Spallanzani IRCCS	Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS	Maria R. Capobianchi, Cesare E. M. Gruber, Martina Rucca, Fabrizio Carletti, Barbara Bartolini, Francesco Messina, Emanuela Gombi, Francesca Colavita, Concetta Castilletti, Eleonora Lalle, Emanuele Nicastri, Giuseppe Ippolito
EPI_ISL_413488	hCoV-19/Germany/NRW-01/2020	Europe / Germany / North Rhine-Westphalia	2020-02-26	Center of Medical Microbiology, Virology, and Hospital Hygiene, University of Dusseldorf	Center of Medical Microbiology, Virology, and Hospital Hygiene, University of Dusseldorf	Ortwin Adams, Marcel Andree, Alexander Dithmer, Torsten Felst, Sandra Hauke, Torsten Houwaart, Björn-Erik Jensen, Delfie Kindgen-Miles, Maite Kohne Vasconcelos, Klaus Pfeffer, Tina Sentf, Daniel Snelow, Jörg Timm, Andreas Walker, Tobias Wiemann
EPI_ISL_413997	hCoV-19/Switzerland/GE3895/2020	Europe / Switzerland / Geneva	2020-02-26	Laboratoire de Virologie, HUG	Swiss National Reference Centre for Influenza	LAUBSCHER Florian et al.
EPI_ISL_414019	hCoV-19/Switzerland/GE3121/2020	Europe / Switzerland / Geneva	2020-02-27	Laboratoire de Virologie, HUG	Swiss National Reference Centre for Influenza	LAUBSCHER Florian et al.
EPI_ISL_414022	hCoV-19/Switzerland/GE9586/2020	Europe / Switzerland / Geneva	2020-02-27	Laboratoire de Virologie, HUG	Swiss National Reference Centre for Influenza	LAUBSCHER Florian et al.
EPI_ISL_414598	hCoV-19/Spain/Valencia3/2020	Europe / Spain / Comunidad Valencia	2020-03-05	Servicio Microbiología, Hospital Clínico Universitario, Valencia	Sequencing and Bioinformatics Service and Molecular Epidemiology Research Group, FISABIO-Public Health	David Navarro, Maria Alma Bracho, Giuseppe D'Auria, Griselda De Marco, Neira Garcia-Gonzalez, Fernando Gonzalez-Candelas
EPI_ISL_414629	hCoV-19/France/HF1870/2020	Europe / France / Hauts de France	2020-03-03	Centre Hospitalier Compigne Laboratoire de Biologie	National Reference Center for Viruses of Respiratory Infections, Institut Pasteur, Paris	Milanie Albert, Marion Barbet, Sylvie Behilli, Meline Bizard, Angela Brisebarre, Flora Donati, Vincent Enouf, Maud Vanpeene, Sylvie van der Werf, Raulin Olivia Bigallon
EPI_ISL_415455	hCoV-19/Switzerland/GE0199/2020	Europe / Switzerland	2020-02-28	Hôpitaux universitaires de Genève Laboratoire de Virologie	Hôpitaux universitaires de Genève Laboratoire de Virologie	Laubscher F.
EPI_ISL_415650	hCoV-19/France/IDF2075/2020	Europe / France / IDF	2020-03-02	Hôpital Instruction des Armées - BEGIN	National Reference Center for Viruses of Respiratory Infections, Institut Pasteur, Paris	Milanie Albert, Marion Barbet, Sylvie Behilli, Meline Bizard, Angela Brisebarre, Flora Donati, Vincent Enouf, Maud Vanpeene, Sylvie van der Werf, Christine Bigallon
EPI_ISL_417921	hCoV-19/Italy/INMI3/2020	Europe / Italy / Rome	2020-03-01	INMI Lazzaro Spallanzani IRCCS	Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS	Martina Rucca, Barbara Bartolini, Francesco Messina, Cesare E. M. Gruber, Emanuela Gombi, Maria R. Capobianchi, Fabrizio Carletti, Francesca Colavita, Concetta Castilletti, Eleonora Lalle, Daniele Lapa, Giuseppe Ippolito
EPI_ISL_417922	hCoV-19/Italy/INMI4/2020	Europe / Italy / Rome	2020-02-28	INMI Lazzaro Spallanzani IRCCS	Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS	Cesare E. M. Gruber, Martina Rucca, Barbara Bartolini, Francesco Messina, Emanuela Gombi, Maria R. Capobianchi, Fabrizio Carletti, Francesca Colavita, Concetta Castilletti, Eleonora Lalle, Daniele Lapa, Giuseppe Ippolito
EPI_ISL_420563	hCoV-19/Italy/TE5166/2020	Europe / Italy / Teramo	2020-03-19	Ospedale Civile Giuseppe Mazzini	Institute Zooprofilattico Sperimentale dell'Abruzzo e Molise "G. Caporale"	Leonisa A. Mancuso M. Di Domenico M. Ancora M. Cioni V. Mangione I. Rosalia A. Di Pasquale A. Cammà C. Puglia I. Savini G.

681
682

683
684 1. Ambrosioni J, Bridevaux PO, Wagner G, Mamin A, Kaiser L. Epidemiology of viral
685 respiratory infections in a tertiary care centre in the era of molecular diagnosis, Geneva,
686 Switzerland, 2011-2012. Clin Microbiol Infect. 2014;20(9):O578-84.
687 2. Zaharia M, Bolosky W, Curtis K, Fox A, Patterson D, Shenker S, et al. Faster and More
688 Accurate Sequence Alignment with SNAP. arXiv:11115572 2011.
689 3. Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for
690 the rapid and sensitive determination of multi-species type I interferon. PloS one.
691 2011;6(10):e25858.
692 4. Torriani G, Trofimenko E, Mayor J, Fedeli C, Moreno H, Michel S, et al. Identification of
693 Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion. Journal of virology.
694 2019;93(6).
695 5. Fukushi S, Mizutani T, Saijo M, Matsuyama S, Miyajima N, Taguchi F, et al. Vesicular
696 stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein.
697 The Journal of general virology. 2005;86(Pt 8):2269-74.
698
699